Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity

Area of Science:

• Pulmonary Medicine
• Metabolic Disorders
• Immunology

Background:

• Obesity, characterized by excess adipose tissue, is a chronic disease impacting multiple organs, including the lungs.
• Abdominal obesity restricts diaphragm movement, reducing lung volume and increasing respiratory disease risk (e.g., COPD, asthma, sleep apnea).
• Adipose tissue dysfunction in obesity promotes metabolic disorders and systemic inflammation via altered adipokine secretion.

Purpose of the Study:

• To investigate the intricate relationship between adipose tissue and lung function in obesity.
• To highlight key inflammatory mediators involved in obesity-induced pulmonary dysfunction.
• To identify novel therapeutic targets for preventing lung complications in obese individuals.

Main Methods:

• Literature review focusing on the interplay between adipose tissue and lung in obesity.
• Analysis of inflammatory pathways, including adipokines and the NLRP3 inflammasome.
• Examination of mechanical and metabolic consequences of obesity on respiratory health.

Main Results:

• Obesity-induced adipose tissue dysfunction leads to systemic inflammation, affecting pulmonary immune responses.
• Adipokines secreted by dysfunctional adipose tissue contribute to airway hyperresponsiveness.
• The NLRP3 inflammasome is implicated as a key mediator of inflammation in both adipose and lung tissues during obesity.

Conclusions:

• Obesity-related adipose tissue dysfunction significantly contributes to pulmonary dysfunction through mechanical and inflammatory mechanisms.
• Targeting inflammatory mediators, such as those involving the NLRP3 inflammasome, presents a promising therapeutic strategy.
• Understanding the adipose-lung crosstalk is crucial for developing interventions against obesity-related respiratory diseases.